NASDAQ:QDEL QuidelOrtho (QDEL) Stock Price, News & Analysis → Your Next Portfolio Star: Revealing 2024's Top Stock Pick (From Darwin) (Ad) Free QDEL Stock Alerts $38.71 -1.59 (-3.95%) (As of 04/17/2024 ET) Add Compare Share Share Today's Range$38.67▼$40.3550-Day Range$38.71▼$69.5452-Week Range$38.67▼$95.02Volume754,587 shsAverage Volume1.01 million shsMarket Capitalization$2.59 billionP/E RatioN/ADividend YieldN/APrice Target$61.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get QuidelOrtho alerts: Email Address QuidelOrtho MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside59.1% Upside$61.60 Price TargetShort InterestHealthy3.36% of Shares Sold ShortDividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews Sentiment0.13Based on 19 Articles This WeekInsider TradingAcquiring Shares$99,652 Bought Last QuarterProj. Earnings Growth73.73%From $2.36 to $4.10 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.91 out of 5 starsMedical Sector17th out of 913 stocksDiagnostic Substances Industry1st out of 11 stocks 4.0 Analyst's Opinion Consensus RatingQuidelOrtho has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 3 hold ratings, and 2 sell ratings.Amount of Analyst CoverageQuidelOrtho has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.36% of the outstanding shares of QuidelOrtho have been sold short.Short Interest Ratio / Days to CoverQuidelOrtho has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in QuidelOrtho has recently decreased by 7.79%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldQuidelOrtho does not currently pay a dividend.Dividend GrowthQuidelOrtho does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreQuidelOrtho has received a 49.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Sexually transmitted diseases quick tests", "Lactose intolerance quick tests", and "Respiratory tract infection tests" products. See details.Environmental SustainabilityThe Environmental Impact score for QuidelOrtho is -2.61. Previous Next 1.7 News and Social Media Coverage News SentimentQuidelOrtho has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for QuidelOrtho this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for QDEL on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added QuidelOrtho to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, QuidelOrtho insiders have bought more of their company's stock than they have sold. Specifically, they have bought $99,652.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.00% of the stock of QuidelOrtho is held by insiders.Percentage Held by Institutions99.00% of the stock of QuidelOrtho is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for QuidelOrtho are expected to grow by 73.73% in the coming year, from $2.36 to $4.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of QuidelOrtho is -241.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of QuidelOrtho is -241.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuidelOrtho has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIThis company has increased its dividend every year for 54 yearsThere are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.Click here to get them (for Free). About QuidelOrtho Stock (NASDAQ:QDEL)QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.Read More QDEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QDEL Stock News HeadlinesApril 17, 2024 | markets.businessinsider.comINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the FirmApril 17, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of QuidelOrtho Corporation (QDEL) InvestorsApril 18, 2024 | DTI (Ad)This company has increased its dividend every year for 54 yearsThere are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.April 17, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of QuidelOrtho Corporation (QDEL) InvestorsApril 17, 2024 | finance.yahoo.comQuidelOrtho To Report First Quarter 2024 Financial ResultsApril 17, 2024 | nasdaq.comBenjamin Graham Detailed Fundamental Analysis - QDELApril 17, 2024 | markets.businessinsider.comIMPORTANT DEADLINE ALERT: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the FirmApril 16, 2024 | stockhouse.comQDEL DEADLINE ALERT: Bernstein Liebhard LLP Reminds QuidelOrtho Corporation Investors of Upcoming DeadlineApril 18, 2024 | DTI (Ad)This company has increased its dividend every year for 54 yearsThere are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.April 16, 2024 | msn.comClass Action Filed Against QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) Seeking Recovery for Investors – Contact Levi & Korsinsky LLPApril 16, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of QuidelOrtho Corporation (QDEL) InvestorsApril 16, 2024 | markets.businessinsider.comINVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the FirmApril 15, 2024 | prnewswire.comQDEL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that QuidelOrtho Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!April 15, 2024 | businesswire.comROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – QDELApril 13, 2024 | businesswire.comLabaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Corporation and Certain ExecutivesApril 13, 2024 | seekingalpha.comQuidelOrtho: Attractive Valuation Despite Weak PerformanceApril 13, 2024 | ca.finance.yahoo.comCAH May 2024 120.000 callApril 12, 2024 | businesswire.comLabaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Company and Certain ExecutivesApril 12, 2024 | investing.comQuidelOrtho launches rapid fentanyl test for hospitalsApril 10, 2024 | prnewswire.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation - QDELApril 10, 2024 | finance.yahoo.comQuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership AssayApril 3, 2024 | markets.businessinsider.comROSEN, NATIONAL INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation - QDELApril 3, 2024 | finance.yahoo.comThis QuidelOrtho Insider Increased Their Holding By 54% Last YearApril 2, 2024 | prnewswire.comROSEN, LEADING INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation - QDELApril 2, 2024 | msn.comQuidelOrtho stock falls 11% on Savanna PVP4+ assay updateApril 2, 2024 | msn.comWhat's Going With COVID-19 Test Maker QuidelOrtho Stock On Tuesday?April 2, 2024 | markets.businessinsider.comQuidelOrtho Receives FDA Clearance For QuickVue COVID-19 Test - Quick FactsSee More Headlines Receive QDEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2024Today4/17/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:QDEL CUSIP74838J10 CIK353569 Webwww.quidel.com Phone(800) 874-1517Fax858-453-4338Employees7,100Year Founded1979Price Target and Rating Average Stock Price Target$61.60 High Stock Price Target$81.00 Low Stock Price Target$37.00 Potential Upside/Downside+59.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.16) Trailing P/E RatioN/A Forward P/E Ratio16.40 P/E GrowthN/ANet Income$-10,100,000.00 Net Margins-0.34% Pretax Margin-0.97% Return on Equity5.54% Return on Assets3.21% Debt Debt-to-Equity Ratio0.45 Current Ratio1.57 Quick Ratio0.88 Sales & Book Value Annual Sales$3.00 billion Price / Sales0.86 Cash Flow$10.27 per share Price / Cash Flow3.77 Book Value$74.92 per share Price / Book0.52Miscellaneous Outstanding Shares66,880,000Free Float66,210,000Market Cap$2.59 billion OptionableOptionable Beta0.11 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Robert J. Bujarski J.D. (Age 55)Interim President, Executive VP & COO Comp: $2.62MMr. Joseph M. Busky CPA (Age 56)Chief Financial Officer Comp: $1.47MMs. Michelle A. Hodges (Age 63)Senior VP, General Counsel & Secretary Comp: $1.8MDr. Werner Kroll Ph.D. (Age 67)Senior Vice President of Research & Development Comp: $1.25MMr. Michael S. Iskra (Age 54)Interim CEO, Executive VP & Chief Commercial Officer Ms. Louise M. BrandyChief Information OfficerMr. Patrick E. KleinChief Administrative OfficerRuben ArguetaDirector of Investor RelationsMr. William J. Ferenczy (Age 68)Point of Care Business Unit Leader Ms. Tamara A. Ranalli (Age 51)Molecular Diagnostics Business Unit Leader More ExecutivesKey CompetitorsNeogenNASDAQ:NEOGCelldex TherapeuticsNASDAQ:CLDXIntellia TherapeuticsNASDAQ:NTLAMyriad GeneticsNASDAQ:MYGNMeridian BioscienceNASDAQ:VIVOView All CompetitorsInsiders & InstitutionsCWM LLCBought 2,642 shares on 4/5/2024Ownership: 0.004%GAMMA Investing LLCBought 1,329 shares on 4/5/2024Ownership: 0.002%PNC Financial Services Group Inc.Sold 590 shares on 3/22/2024Ownership: 0.007%Vanguard Group Inc.Bought 44,770 shares on 3/11/2024Ownership: 7.242%Wellington Management Group LLPSold 132,222 shares on 3/5/2024Ownership: 0.940%View All Insider TransactionsView All Institutional Transactions QDEL Stock Analysis - Frequently Asked Questions Should I buy or sell QuidelOrtho stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for QuidelOrtho in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" QDEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QDEL, but not buy additional shares or sell existing shares. View QDEL analyst ratings or view top-rated stocks. What is QuidelOrtho's stock price target for 2024? 7 analysts have issued 1-year price targets for QuidelOrtho's stock. Their QDEL share price targets range from $37.00 to $81.00. On average, they predict the company's stock price to reach $61.60 in the next twelve months. This suggests a possible upside of 59.1% from the stock's current price. View analysts price targets for QDEL or view top-rated stocks among Wall Street analysts. How have QDEL shares performed in 2024? QuidelOrtho's stock was trading at $73.70 at the beginning of the year. Since then, QDEL stock has decreased by 47.5% and is now trading at $38.71. View the best growth stocks for 2024 here. When is QuidelOrtho's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our QDEL earnings forecast. How were QuidelOrtho's earnings last quarter? QuidelOrtho Co. (NASDAQ:QDEL) announced its quarterly earnings data on Tuesday, February, 13th. The company reported $1.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.01 by $0.84. The business had revenue of $742.60 million for the quarter, compared to analysts' expectations of $796.91 million. QuidelOrtho had a negative net margin of 0.34% and a positive trailing twelve-month return on equity of 5.54%. The business's revenue was down 14.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.74 EPS. What ETFs hold QuidelOrtho's stock? ETFs with the largest weight of QuidelOrtho (NASDAQ:QDEL) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), First Trust Health Care AlphaDEX Fund (FXH), SPDR S&P Health Care Equipment ETF (XHE), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and Ballast Small/Mid Cap ETF (MGMT).iShares U.S. Medical Devices ETF (IHI). What guidance has QuidelOrtho issued on next quarter's earnings? QuidelOrtho updated its FY 2024 earnings guidance on Tuesday, February, 13th. The company provided earnings per share (EPS) guidance of 2.400-3.070 for the period, compared to the consensus earnings per share estimate of 5.070. The company issued revenue guidance of $2.8 billion-$3.1 billion, compared to the consensus revenue estimate of $3.0 billion. What is Doug Bryant's approval rating as QuidelOrtho's CEO? 47 employees have rated QuidelOrtho Chief Executive Officer Doug Bryant on Glassdoor.com. Doug Bryant has an approval rating of 76% among the company's employees. What other stocks do shareholders of QuidelOrtho own? Based on aggregate information from My MarketBeat watchlists, some companies that other QuidelOrtho investors own include NVIDIA (NVDA), DocuSign (DOCU), Tesla (TSLA), PayPal (PYPL), Shopify (SHOP), Block (SQ), Teladoc Health (TDOC), Netflix (NFLX), Advanced Micro Devices (AMD) and Zoom Video Communications (ZM). Who are QuidelOrtho's major shareholders? QuidelOrtho's stock is owned by many different institutional and retail investors. Top institutional investors include CWM LLC (0.00%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Charles P Slacik, Joseph M Busky, Mary Lake Ph D Polan and William J Ferenczy. View institutional ownership trends. How do I buy shares of QuidelOrtho? Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:QDEL) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeBiden out June 13; Kamala won’t replace him?Paradigm PressTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsUrgent alert: open this for a huge profit potentialTimothy SykesYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding QuidelOrtho Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.